Alemtuzumab therapy changes immunoglobulin levels in peripheral blood and CSF
Citation Manager Formats
Make Comment
See Comments

Article Information
- Received June 24, 2019
- Accepted in final form November 4, 2019
- First Published December 11, 2019.
Author Disclosures
- Nora Möhn, MD*,
- Steffen Pfeuffer, MD*,
- Tobias Ruck, MD,
- Catharina C. Gross, PhD,
- Thomas Skripuletz, MD,
- Luisa Klotz, MD,
- Heinz Wiendl, MD,
- Martin Stangel, MD* and
- Sven G. Meuth, MD, PhD*
- Nora Möhn, MD*,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Steffen Pfeuffer, MD*,
NONE
NONE
Commercial entity: Travel grants by Sanofi Genzyme, Merck, Biogen, Mylan
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
Commercial entity: Research support from DIAMED ans Merck Serono
NONE
NONE
Society: Research support from the German Multiple Sclerosis Society (DMSG)
NONE
NONE
NONE
NONE
NONE
NONE
- Tobias Ruck, MD,
TR served on a scientific advisory board for Genzyme, Merck and Novartis.
NONE
TR has received travel expenses from Genzyme and Novartis and has received honoraria for lecturing from Genzyme, Biogen and Teva.
Guest associate editor for Frontiers in Neurology.
NONE
NONE
NONE
NONE
NONE
NONE
NONE
TR has received financial research support from Genzyme and Novartis.
NONE
NONE
Supported by the German Ministry of Education, Science, Research and Technology (01GI1603D, to T.R. and S.G.M.; FKZ01FI1603A to HW, LK, and CCG)
NONE
NONE
NONE
NONE
NONE
NONE
- Catharina C. Gross, PhD,
NONE
NONE
I received speaker honoraria and travel expenses for attending meetings from Biogen, Euroimmun, Genzyme, Mylan, Novartis Pharma GmbH, and Bayer Health Care.
Frontiers in Immunology, Review Editor, Since 2015
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
EU Horizon 2020 ReSTORE German Research Foundation (DFG), GR3946/3-1, 01/2018- 12/2020 German Research Foundation (DFG), GR3946/2-1, 01/2013- 12/2015 German Research Foundation (DFG), SFB-CRC-TR 129,Project A09 07/2016-06/2020 BMBF grant Disease-Related Competence Network Multiple Sclerosis, Immune MS, KKNMS-030
The Interdisciplinary Center for Clinical Studies (IZKF) Innovative Medical Science Grant (IMF-grant) of the medical faculty of the University of Münster, KL111421, 07/2014-06/2016
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Thomas Skripuletz, MD,
NONE
NONE
Speaker honoraria: Alexion Pharma Germany GmbH, Bayer Vital GmbH, CSL Behring GmbH, Roche Pharma AG, Merck Serono GmbH, Sanofi Aventis Deutschland GmbH. All outside the submitted work.
Guest Editor 2018/2019: Frontiers in Neurology, Special Topic: New Cerebrospinal Fluid Research to Uncover Mechanisms Driving Neurological and Psychiatric Diseases
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Luisa Klotz, MD,
(1) Genzyme (2) Novartis (3) Roche (4) Merck (5) Janssen (6) Alexion
NONE
(1) Novartis, speaker honoraria and travel support (2) Merck Serono, speaker honoraria and travel support (3) Biogen, speaker honoraria and travel support (4) Roche, speaker honoraria and travel support (5) Genzyme, speaker honoraria and travel support (6) Teva, speaker honoraria and travel support (7) Janssen, speaker honoraria and travel support (8) Santhera, speaker honoraria and travel support (9) Grifols, speaker honoraria and travel support (10)Alexion, speaker honoraria and travel support
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
(1) Novartis (2) Biogen (3) Merck
(1) (CRC) SFB TR-128 Impact of dietary factors on the gut-CNS-axis  implications for CNS autoimmunity A08, Project leader, 2016-2020 (2) (CRC) SFB 1009 ÂImmune-cell interactions with endothelial cells and pericytes at the blood-brain- barrier: mechanisms and consequences A03, Sub-project Leader, 2012-2020 (3) CRC; ÂThe role of the nuclear receptor NR4A1 in acute ischemic stroke: pathophysiology, therapy evaluation and human translation';Sub-Project leader, 2018-2020 (4) Federal Ministry of Education and Research (BMBF) Competence Network Multiple Sklerose: ÂMulti-parameter immune cell-profiling: identification of biosignatures to understand heterogeneity, prognosis and treatment response factors in MSÂ, 3.1 Sub-project Leader, 2016-2020 (5) Interdisciplinary Centre for Clinical Research, Münster (IZKF),"Antigen-specific CDS T-cell responses in Neuromyelits Optica and Susac Syndrome", Sub-Project leader, 2019-2021 (6) Innovative Medical Research(IMF) Münster,"Farnesoid X receptor (FXR)-induced anti-inflammatory monocyte polarization relevance for autoimmunity", Project-leader, 2019-2021 (7)CRC;"ImmunoStroke: From immune Cells to Stroke Recovery" Sub-Project leader, since 2019 (8)CRC: Organ dysfuncion during systemic inflammation: Immune system variables in healthy subjects and during systemic inflammation Sub-Project leader, 2020-2023
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Heinz Wiendl, MD,
(1) Biogen, (2) Evgen (3) MedDay Pharmaceuticals (4) Merck Serono (5) Novartis (6) Roche Pharma AG (7) Sanofi-Genzyme
NONE
(1) Alexion (2) Biogen (3) Cognomed (4) F. Hoffmann-La Roche Ltd. (5) Gemeinnützige Hertie-Stiftung (6) Merck Serono (7) Novartis (8) Roche Pharma AG (9) Sanofi-Genzyme (10) TEVA (11) WebMD Global
(1) PLOS ONE, Editorial board member, since 2013 (2) Neurotherapeutics, since 2013 (3) Recent Patents on Inflammation & Allergy Drug Discovery
NONE
NONE
NONE
(1) Abbvie (2) Biogen (3) IGES (4) Johnson & Johnson (5) Merck (6) Novartis (7) Roche (8) Sanofi-Genzyme (9) Swiss Multiple Sclerosis Society
NONE
NONE
NONE
(1) Bayer Healthcare (2) Bayer Vital (3) Biogen (4) Merck Serono (5) Novartis (6) Sanofi  Genzyme (7) Sanofi US (8) TEVA Pharma
(1) German Ministry for Education and Research (BMBF), 01GI1601E, principal investigator, 2016-2019 (2)Interdisciplinary Centre of Clinical Research (IZKF) Muenster, principal investigator, 2015-2018 (4)PML Consortium, principal investigator, 2016-2018 (5) German Research Foundation, principal investigator,SFB 1009 TP A3 + SFB-TR CRC128 TP A09 + SFB TR CRC128 TP A10, TR CRC128 TP V, TR CRC128 TP Z02 2016- 2020
NONE
(1) Else Kröner Fresenius Foundation (2) Fresenius Foundation (3) Hertie Foundation (4) RE ChildrenÂs Foundation
NONE
NONE
NONE
NONE
NONE
NONE
- Martin Stangel, MD* and
Alexion, Biogen, Bayer Healthcare, Baxalta/Shire/Takeda, Celgene, CSL Behring, Grifols, Janssen, MedDay, Merck- Serono, Novartis, Roche, Sanofi-Genzyme
NONE
Travel and speaker honoraria from Bayer Healthcare, Biogen, CSL Behring, Merck-Serono, Novartis, Roche, Sanofi-Genzyme, and Teva
PLoS ONE, Academic Editor; Multiple Sclerosis International, Editorial Board Member
NONE
NONE
NONE
NONE
NONE
NONE
NONE
Biogen, Merck-Serono, Novartis, Sanofi-Genzyme
Deutsche Forschungsgemeinschaft (DFG), Bundesministerium für Bildung und Forschung (BMBF), EU FP7
NONE
Volkswagenstiftung
NONE
NONE
NONE
NONE
NONE
NONE
- Sven G. Meuth, MD, PhD*
(1) German association for Multiple Sclerosis (2) German Society for Neurology (DGN)(3) Neurology Trust (4) Center for Clinical Studies (ZKS) (5) Max Planck Society
NONE
Sven Meuth receives honoraria for lecturing, and travel expenses for attending meetings from Almirall, Amicus Therapeutics Germany, Bayer Health Care, Biogen, Celgene, Diamed, Genzyme, MedDay Pharmaceuticals, Merck Serono, Novartis, Novo Nordisk, ONO Pharma, Roche, Sanofi- Aventis, Chugai Pharma, QuintilesIMS and Teva.
(1) PLoS One (editor) (2) DGNeurologie, founding member editorial board
(1)Effectivity of specific FXII/FXIIa inhibitors, particularly rHA-Infestin 4 used to treat neuro- inflammatoral diseases (WO 2013/113774 A1 and EP 2 263 110 A1) (2) Diagnosis of a novel autoimmune disease (European patent; 15001186.4  1402) (3)"NR2B selective NMDA-receptor Antagonists for Treatment of immune-mediated inflammatory diseases (Reference number: PCT/EP2016/069975)
NONE
NONE
Sven Meuth receives honoraria for lecturing, and travel expenses for attending meetings from Almirall, Amicus Therapeutics Germany, Bayer Health Care, Biogen, Celgene, Diamed, Genzyme, MedDay Pharmaceuticals, Merck Serono, Novartis, Novo Nordisk, ONO Pharma, Roche, Sanofi- Aventis, Chugai Pharma, QuintilesIMS and Teva.
NONE
NONE
NONE
Research is funded by Almirall, Amicus Therapeutics Germany, Biogen, Diamed, Fresenius Medical Care, HERZ Burgdorf, Genzyme, Merck Serono, Novartis, ONO Pharma, Roche, and Teva.
Research is funded by the German Ministry for Education and Research (BMBF), Deutsche Forschungsgesellschaft (DFG), German Academic Exchange Service, Interdisciplinary Center for Clinical Studies (IZKF) Muenster, German Foundation Neurology, Bundesinstitut für Risikobewertung; Gemeinsamer Bundesausschuss
NONE
Research is funded by Else Kröner Fresenius Foundation, Hertie Foundation
NONE
NONE
NONE
NONE
NONE
NONE
- From the Department of Neurology and Clinical Neuroimmunology and Neurochemistry (N.M., T.S., M.S.), Hannover Medical School, Hannover, Germany; and Neurology Clinic with Institute of Translational Neurology (S.P., T.R., C.C.G., L.K., H.W., S.G.M.), University of Münster, Münster, Germany.
- Correspondence
Dr. Stangel Stangel.Martin{at}mh-hannover.de
Article usage
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Hastening the Diagnosis of Amyotrophic Lateral Sclerosis
Dr. Brian Callaghan and Dr. Kellen Quigg
► Watch
Related Articles
- No related articles found.
Topics Discussed
Alert Me
Recommended articles
-
Article
Alemtuzumab long-term immunologic effectTreg suppressor function increases up to 24 monthsStefania De Mercanti, Simona Rolla, Angele Cucci et al.Neurology - Neuroimmunology Neuroinflammation, January 21, 2016 -
Article
Lymphocyte pharmacodynamics are not associated with autoimmunity or efficacy after alemtuzumabHeinz Wiendl, Matthew Carraro, Giancarlo Comi et al.Neurology: Neuroimmunology & Neuroinflammation, October 29, 2019 -
Article
Alemtuzumab CARE-MS II 5-year follow-upEfficacy and safety findingsAlasdair J. Coles, Jeffrey A. Cohen, Edward J. Fox et al.Neurology, August 23, 2017 -
Article
Effects of Natalizumab Therapy on Intrathecal Immunoglobulin G Production Indicate Targeting of PlasmablastsMiriam Schlüter, Eva Oswald, Stephan Winklmeier et al.Neurology: Neuroimmunology & Neuroinflammation, July 01, 2021